Mineralys Therapeutics Announces NDA Submission and $201M Equity Raise Amid Financial Challenges
Mineralys Therapeutics Inc. is navigating financial challenges while making bold strides towards innovation, including an NDA submission and $201 million equity raise, as it aims to bring its aldosterone synthase inhibitor to market.
3 minutes to read